Subhash, Pinki and Ashu Chaudhary^*,

Department of Chemistry, Kurukshetra University, Kurukshetra-136119, India

*Corresponding author: E-mail: ashuchaudhary21@gmail.com; ashuchaudhary@kuk.ac.in

Animated number of passing and affirmed instances of COVID-19 requires an earnest interest in viable and accessible medications for SARS-CoV-2 treatment. On the way to that activity, potential medications alike ivermectin, hydroxychloroquine and azithromycin have been tried by assorted groups of analysts universal for their probable in contradiction of novel COVID. The point of this survey is to portray the pharmacologic instrument, medical proof and recommending rules relating to azithromycin in Coronavirus affected role. Antiviral and immunomodulatory impacts of azithromycin is less proved, which moreover did not depend on outcomes from Coronavirus patients explicitly. Azithromycin is a manufactured macrolide anti-toxin compelling against an expansive scope of bacterial and mycobacterial contaminations. Because of an extra scope as antiviral and anti-inflammatory assets, that's why it given to patient with the COVIDS MERS-CoV or SARS-CoV. Here, we rundowns information from in murine, vitro and human clinical investigations on the counter popular and mitigating characteristics of macrolides, especially azithromycin. Azithromycin decreases in vitro repetition of a few classes of infections together with influenza A, rhinovirus, Zika infection, Ebola and COVIDS. These properties could be helpful all through the COVID-19. The azithromycin a macrolide presents a notable wellbeing outline. Forthcoming medical preliminaries will decide the part of this macrolide in the Coronavirus.

Azithromycin, Antiviral effects, Macrolide, COVID-19, Zika virus, Ebola virus, Pharmacological mechanism.